Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IQP-0528 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that has potential for the treatment of HIV infection by blocking viral entry and shows antiviral activity as a microbicidal gel. . IQP-0528 showed inhibition of both HIV-1 and HIV-2, with an EC50 of 0.2 nM for HIV-1 and 100 nM for HIV-2.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 133.00 | |
5 mg | In stock | $ 320.00 | |
10 mg | In stock | $ 480.00 | |
25 mg | In stock | $ 786.00 | |
50 mg | In stock | $ 1,080.00 | |
100 mg | In stock | $ 1,480.00 | |
500 mg | In stock | $ 2,960.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 328.00 |
Description | IQP-0528 is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI) that has potential for the treatment of HIV infection by blocking viral entry and shows antiviral activity as a microbicidal gel. . IQP-0528 showed inhibition of both HIV-1 and HIV-2, with an EC50 of 0.2 nM for HIV-1 and 100 nM for HIV-2. |
Targets&IC50 | HIV-1:0.2 nM(EC50), HIV-2:100 nM(EC50) |
In vitro | The in vitro safety evaluations showed no significant loss in cell viability or significant inflammatory response after treatment with a 3.0% HEC gel containing 0.25% IQP-0528. In an in vitro HIV-1 entry inhibition assay, the lead formulation showed an 50% effective concentration of 0.14 μg/ml for gel in culture media, which corresponds to ∼0.001 μM IQP-0528.[5] |
In vivo | we report the first-in-human evaluation of such a gel containing 1% IQP-0528, an investigational antiretroviral. Seven HIV-1-negative participants received one 10 mL rectal dose of radiolabeled 1% IQP-0528 gel. Median IQP-0528 concentrations in rectal tissue exceeded the in vitro EC95 against HIV-1 (0.07 ng/mg) by 3-5 h of dosing and remained above this concentration for at least 24 h, despite a 3-log reduction in concentration over this duration of time. Rectal tissue PD assessed by ex vivo HIV challenge-demonstrated significant p24 antigen reduction 3-5 h postdose compared with baseline , but not 24-26 h postdose. The IQP-0528 gel possesses desirable features for a topical microbicide including local safety with no systemic absorption, delivery of locally high IQP-0528 concentrations, and significant reductions in ex vivo HIV infectivity.[6] |
Synonyms | SJ-3991, SJ3991, IQP0528 |
Molecular Weight | 340.42 |
Formula | C20H24N2O3 |
CAS No. | 301297-45-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 4 mg/mL (11.75 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IQP-0528 301297-45-0 Immunology/Inflammation Microbiology/Virology Proteases/Proteasome Antiviral HIV Protease Reverse Transcriptase SJ 3991 IQP 0528 SJ-3991 SJ3991 IQP0528 inhibitor inhibit